You're not alone: Saskatoon and central Saskatchewan have a vibrant Crohn’s and colitis community, made up of people with inflammatory bowel disease, families, volunteers, and more. Throughout the year, we come together at meetings and events like the Gutsy Walk to share experiences, raise funds and heighten awareness.

There are an estimated 1,700 people with Crohn’s disease or ulcerative colitis in the communities of Central Saskatchewan. We understand the challenges you and your family may be facing – because we face them, too.
Group of friends who are older adults chatting with each other

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?  Join our upcoming Peer Connect event ...

 • 
Virtual
 • 
Woman sitting on her bed looking at her laptop holding a coffee cup

Saskatchewan Peer Connect Event (With Manitoba)

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?  Join our upcoming Peer Connect ...

 • 
Virtual
 • 
Woman sitting looking at her computer

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   Join our upcoming Peer Connect ...

 • 
Virtual
 • 

Facebook

More on Facebook
 
Remember to bookmark this page.

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada

 12 13 14 15 16 17 18 19 20 21